Showing 2640 results
- Story /
Novartis immunologist describes the excitement of discovering a promising new immuno-oncology (IO) target in the treatment of acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).
- Key Release /Annonce événementielle selon l’art. 53 RC Chiffre d’affaires net du 4e trimestre en hausse de +6% (tcc1, +4% USD) et résultat opérationnel core croissant de +12% (tcc1, +9% USD) Innovative…
- Key Release /Ad-hoc-Mitteilung gemäss Art. 53 KR Im vierten Quartal stieg der Umsatz um +6% (kWk1, +4% USD), das operative Kernergebnis wuchs um +12% (kWk, +9% USD) Innovative Medicines steigerte den…
- Key Release /Ad hoc announcement pursuant to Art. 53 LRPhase III APPLY-PNH trial met its two primary endpoints for superiority versus anti-C5 treatment in adult paroxysmal nocturnal hemoglobinuria (PNH) patients…
- Media Release /Phase III VISION trial showed Pluvicto® plus best standard of care significantly improved survival for patients with pre-treated PSMA-positive mCRPC1 Approximately 473,000 prostate cancer cases and…
- Media Release /Transformation to pure-play Innovative Medicines company nears completion Focusing strategy on five core Therapeutic Areas, key technology platforms, and the US Advancing eight in-…
- Key Release /Ad hoc announcement pursuant to Art. 53 LR Basel, 21 September, 2022 — Today, Novartis announced that the U.S. Court of Appeals for the Federal Circuit (CAFC) has denied its…
- Media Release /ROSALIA study met primary endpoints, confirming proposed biosimilar denosumab matches reference product in terms of pharmacokinetics, pharmacodynamics, efficacy, safety and immunogenicity in…
- Media Release /Company confident to clarify legitimacy of its position and fully cooperating with authorities Basel, September 15, 2022 — Novartis today confirms that it has been contacted by the Swiss…
- Media Release /Multi-year investment of USD 300m will create integrated scientific environment to deliver on increasing growth and diversity of biotherapeutics portfolio Enhanced capacity and processes…
Pagination
- ‹ Previous page
- 1
- …
- 149
- 150
- 151
- 152
- 153
- 154
- 155
- …
- 264
- › Next page